Skip to content

Effects of linggui zhugan Traditional Chinese Medicinal Granules Treatment on Metabolic Syndrome: A Randomized Controlled Clinical Trial

Effects of linggui zhugan Traditional Chinese Medicinal Granules Treatment on Metabolic Syndrome: A Randomized Controlled Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17010580
Enrollment
Unknown
Registered
2017-02-08
Start date
2016-11-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Interventions

Test group:linggui zhugan Traditional Chinese Medicinal Granules
control goup:linggui zhugan decoction pieces

Sponsors

Xiyuan Hospital of China Academy of Chinese Medicine Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) cases meet the Metabolic Syndrome diagnosis standards; (2) cases meet the TCM syndrome of dampness due to spleen deficiency; (3) cases corresponding to Metabolic Syndrome diagnosis standards both in enrollment and 4 weeks after lifestyle modification; (4) FBG=6.1mmol/L(ll0mg/dl) and/or hyperglycemia has been diagnosed; (5) Aged between 18~65 years old; (6) ICF has been signed.

Exclusion criteria

Exclusion criteria: (1) Hyperglycemia with FBG=7mmol/L(126mg/dL) or HA1C=8% after lifestyle modification and medication; (2) TC=6.22mmol/L(240mg/dL) or LDL-C=4.92mmol/L(190mg/dL) or TG=3.39mmol/L(300mg/dL); (3) SBP=160mmHg and/or DBP=100mmHg; (4) Cases of malignant cancer,severe cardiovascular diseases,hematological diseases,cerebrovascular diseases,severe trauma or post major surgeries; (5) Cases of nephrotic syndrome,hypothyroidism,acute/chronic liver & gallbladder diseases or gout; (6) Dyslipidemia induced by drugs(such as phenothiazines,ß-receptor-blocker,adrenal corticosteroids); (7) Abnormality of liver or kidney function(ALT>1.5N or Cr>N(N represents upper limit of normal)); (8) Allergic constitution or be allergic to test medications; (9) Abuse of drugs or alcohol; (10) Active liver diseases or mental illness; (11) Be in other clinical trials in recent three months; (12) Pregnancy, prepare to pregnant or in lactation; (13) Any other unfit conditions judged by investigators.

Design outcomes

Primary

MeasureTime frame
HOMA-IR;FPG;MS sydrome related indicators;TCM symptoms disappearance rate;

Countries

China

Contacts

Public ContactRui Gao

Xiyuan Hospital of China Academy of Chinese Medical Sciences

ruigao@126.com+86 010 62835653

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026